These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

305 related items for PubMed ID: 36481420

  • 1. The Benefit of Complete Response to Treatment in Patients With Chronic Spontaneous Urticaria-CURE Results.
    Kolkhir P, Laires PA, Salameh P, Asero R, Bizjak M, Košnik M, Dissemond J, van Doorn M, Hawro T, Kasperska-Zajac A, Zajac M, Kocatürk E, Peter J, Parisi CAS, Ritchie CA, Kulthanan K, Tuchinda P, Fomina D, Kovalkova E, Khoshkhui M, Kouzegaran S, Papapostolou N, Du-Thanh A, Kamegashira A, Meshkova R, Vitchuk A, Bauer A, Grattan C, Staubach P, Bouillet L, Giménez-Arnau AM, Maurer M, Weller K.
    J Allergy Clin Immunol Pract; 2023 Feb; 11(2):610-620.e5. PubMed ID: 36481420
    [Abstract] [Full Text] [Related]

  • 2. The impact of omalizumab on quality of life and its predictors in patients with chronic spontaneous urticaria: Real-life data.
    Salman A, Demir G, Bekiroglu N.
    Dermatol Ther; 2019 Jul; 32(4):e12975. PubMed ID: 31145524
    [Abstract] [Full Text] [Related]

  • 3. Omalizumab in patients with chronic spontaneous urticaria nonresponsive to H1-antihistamine treatment: results of the phase IV open-label SUNRISE study.
    Bérard F, Ferrier Le Bouedec MC, Bouillet L, Reguiai Z, Barbaud A, Cambazard F, Milpied B, Pelvet B, Kasujee I, Gharbi H, Lacour JP.
    Br J Dermatol; 2019 Jan; 180(1):56-66. PubMed ID: 29927483
    [Abstract] [Full Text] [Related]

  • 4. Comparison of Omalizumab Treatment Response in Patients with Chronic Spontaneous Urticaria and Symptomatic Dermographism: A Single-Center Retrospective Study.
    Cakmak ME, Yeğit OO, Öztop N.
    Int Arch Allergy Immunol; 2023 Jan; 184(3):236-242. PubMed ID: 36543155
    [Abstract] [Full Text] [Related]

  • 5. Real-life data on the effectiveness and safety of omalizumab in monotherapy or combined for chronic spontaneous urticaria: a retrospective cohort study.
    Salman A, Ergun T, Gimenez-Arnau AM.
    J Dermatolog Treat; 2020 Mar; 31(2):204-209. PubMed ID: 30821591
    [Abstract] [Full Text] [Related]

  • 6. Epidemiological and clinical characteristics of adult patients with chronic spontaneous urticaria in Latvia: insights from a two-centre study.
    Sokolovskis A, Lapiņa L, Lauva A, Papirte S, Zolovs M, Ciekure L, Mauliņš E, Lielmane L, Kriķe P, Selicka M, Puriņa S, Kurjāne N.
    Eur J Dermatol; 2024 Aug 01; 34(4):398-408. PubMed ID: 39193677
    [Abstract] [Full Text] [Related]

  • 7. Improvement in the quality of life of patients with chronic spontaneous urticaria treated with omalizumab in real life.
    Larrea-Baca I, Gurpegui-Resano M.
    Enferm Clin; 2017 Aug 01; 27(6):361-368. PubMed ID: 28457893
    [Abstract] [Full Text] [Related]

  • 8. Elevated baseline soluble FcεRI may be linked to early response to omalizumab treatment in chronic spontaneous urticaria.
    Moñino-Romero S, Kolkhir P, Ohanyan T, Szépfalusi Z, Weller K, Metz M, Scheffel J, Maurer M, Altrichter S.
    J Eur Acad Dermatol Venereol; 2024 Jan 01; 38(1):167-174. PubMed ID: 37641982
    [Abstract] [Full Text] [Related]

  • 9. Depression scores change significantly after omalizumab treatment in patients with chronic spontaneous urticaria.
    Can PK, Etikan P, Degirmentepe EN, Kocaturk E.
    Asian Pac J Allergy Immunol; 2024 Jun 01; 42(2):132-137. PubMed ID: 33638627
    [Abstract] [Full Text] [Related]

  • 10. Real-world safety and effectiveness of omalizumab in Japanese patients with chronic spontaneous urticaria: A post-marketing surveillance study.
    Hide M, Fukunaga A, Suzuki T, Nakamura N, Kimura M, Sasajima T, Kiriyama J, Igarashi A.
    Allergol Int; 2023 Apr 01; 72(2):286-296. PubMed ID: 36272899
    [Abstract] [Full Text] [Related]

  • 11. Atopy and Response to Omalizumab Treatment in Chronic Spontaneous Urticaria.
    Costa C, Esteves Caldeira L, Paulino M, Santos DF, Silva SL.
    Int Arch Allergy Immunol; 2024 Apr 01; 185(3):260-266. PubMed ID: 38113870
    [Abstract] [Full Text] [Related]

  • 12. Analysis of clinical factors as possible predictors of response to omalizumab and relapse after treatment discontinuation in chronic spontaneous urticaria.
    Foti C, Romita P, Ambrogio F, Fanelli M, Panebianco R, Vena GA, Cassano N, Ragusa M, Giuffrida R, Papaianni V, Borgia F, Cannavò SP, Guarneri F.
    Dermatol Ther; 2022 Feb 01; 35(2):e15248. PubMed ID: 34877757
    [Abstract] [Full Text] [Related]

  • 13. Antihistamine-resistant chronic spontaneous urticaria remains undertreated: 2-year data from the AWARE study.
    Maurer M, Costa C, Gimenez Arnau A, Guillet G, Labrador-Horrillo M, Lapeere H, Meshkova R, Savic S, Chapman-Rothe N.
    Clin Exp Allergy; 2020 Oct 01; 50(10):1166-1175. PubMed ID: 32735720
    [Abstract] [Full Text] [Related]

  • 14. Omalizumab on Chronic Spontaneous Urticaria and Chronic Inducible Urticaria: A Real-World Study of Efficacy and Predictors of Treatment Outcome.
    Jeong SH, Lim DJ, Chang SE, Kim KH, Kim KJ, Park EJ.
    J Korean Med Sci; 2022 Jul 11; 37(27):e211. PubMed ID: 35818702
    [Abstract] [Full Text] [Related]

  • 15. Effect of omalizumab on angioedema in H1 -antihistamine-resistant chronic spontaneous urticaria patients: results from X-ACT, a randomized controlled trial.
    Staubach P, Metz M, Chapman-Rothe N, Sieder C, Bräutigam M, Canvin J, Maurer M.
    Allergy; 2016 Aug 11; 71(8):1135-44. PubMed ID: 27010957
    [Abstract] [Full Text] [Related]

  • 16. Patients With Chronic Spontaneous Urticaria Who Have Wheals, Angioedema, or Both, Differ Demographically, Clinically, and in Response to Treatment-Results From CURE.
    Buttgereit T, Vera C, Aulenbacher F, Church MK, Hawro T, Asero R, Bauer A, Bizjak M, Bouillet L, Dissemond J, Fomina D, Giménez-Arnau AM, Grattan C, Gregoriou S, Kulthanan K, Kasperska-Zajac A, Kocatürk E, Makris M, Kolkhir P, Weller K, Magerl M, Maurer M.
    J Allergy Clin Immunol Pract; 2023 Nov 11; 11(11):3515-3525.e4. PubMed ID: 37604426
    [Abstract] [Full Text] [Related]

  • 17. The Real-Life Effectiveness and Safety of Omalizumab Updosing in Patients With Chronic Spontaneous Urticaria.
    Salman A, Comert E.
    J Cutan Med Surg; 2019 Nov 11; 23(5):496-500. PubMed ID: 31030540
    [Abstract] [Full Text] [Related]

  • 18. Effectiveness of omalizumab in chronic spontaneous urticaria assessed with patient-reported outcomes: a prospective study.
    Ghazanfar MN, Holm JG, Thomsen SF.
    J Eur Acad Dermatol Venereol; 2018 Oct 11; 32(10):1761-1767. PubMed ID: 29729103
    [Abstract] [Full Text] [Related]

  • 19. Omalizumab in Chronic Spontaneous Urticaria (CSU): Real-Life Experience in Dose/Interval Adjustments and Treatment Discontinuation.
    Brás R, Costa C, Limão R, Caldeira LE, Paulino M, Pedro E.
    J Allergy Clin Immunol Pract; 2023 Aug 11; 11(8):2392-2402. PubMed ID: 36720390
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.